The mesothelium is the protective lining of internal organs. It is where malignant mesothelioma, an uncommon and aggressive disease, forms. Though it can also occur in the peritoneum (the lining of the abdomen), pericardium (the lining of the heart), and tunica vaginalis (the lining of the testicles), it mainly affects the pleura (the lining of the lungs). Exposure to asbestos is the main cause, and symptoms may appear 20–60 years later. The location affects the symptoms, which can include swelling, shortness of breath, chest pain, and abdominal pain. It is a malignancy that is thought to be fatal, and the prognosis is typically poor. Moreover, its rising prevalence is anticipated to positively impact the pipeline landscape for malignant mesothelioma drugs.
Major companies involved in the malignant mesothelioma treatment market include MedImmune LLC., Epizyme Inc. and Ferring Ventures Limited among others.
Leading drugs currently under the pipeline include rAd-IFN and Tazemetostat, among others.
The increasing cases of malignant mesothelioma and the rising technological advancements are poised to positively influence the malignant mesothelioma pipeline landscape.
The Malignant Mesothelioma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into malignant mesothelioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for malignant mesothelioma. The malignant mesothelioma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The malignant mesothelioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with malignant mesothelioma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to malignant mesothelioma.
Malignant mesothelioma is caused by the neoplastic transformation of mesothelial cells, which is frequently brought on by asbestos exposure. Normal cell growth regulation is disrupted by the frequent inactivation or deletion of important tumor suppressor genes, including p16INK4a, p14ARF, NF2, and BAP1. Cell survival and proliferation are fueled by chromosomal anomalies and dysregulation of signaling networks, including the PI3K-AKT, Raf-MEK-ERK, and Hippo pathways. Protein synthesis is improved, and metabolic outputs are reprogrammed by increased translation of mRNAs for ribosome assembly and mitochondrial biogenesis, which further encourages tumor growth. The development of mesothelioma is also influenced by angiogenesis, which is fueled by substances such as vascular endothelial growth factor.
The most preferred type of molecule for the treatment of malignant mesothelioma is small molecule inhibitors, particularly immune checkpoint inhibitors (ICIs) like nivolumab and ipilimumab. These drugs target PD-1/PD-L1 pathways, enhancing the immune system’s ability to attack cancer cells. Small molecules like tyrosine kinase inhibitors (TKIs) are also being explored for targeted therapy. Their advantages include oral bioavailability, specificity, and effectiveness in controlling tumor progression, making them a key component of mesothelioma treatment alongside chemotherapy and immunotherapy. Further, the rising focus on the development of malignant mesothelioma emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
About 3,000 new cases of malignant mesothelioma are discovered in the US each year, making it a rare cancer. In 2019, it made up fewer than 0.2% of all cancer diagnoses in the United States. In the United States, 72,779 new cases were detected between 1999 and 2021. White, Hispanic, and Latino individuals have a higher incidence of mesothelioma. Pleural mesothelioma is diagnosed at an average age of 72, making it more prevalent in older people. Higher percentages are found in states like California that have a history of industrialization or natural asbestos deposits.
This section of the report covers the analysis of malignant mesothelioma drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of malignant mesothelioma drugs undergoing clinical development.
The drug molecule categories covered under malignant mesothelioma pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The malignant mesothelioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for malignant mesothelioma.
The EMR report for the malignant mesothelioma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed malignant mesothelioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in malignant mesothelioma clinical trials:
Major drugs currently in the drug pipeline are as follows:
Ferring Ventures Limited is conducting a Phase 3 clinical trial to assess the efficacy and safety of rAd-IFN, an adenovirus-delivered interferon alpha-2b gene therapy, in combination with celecoxib and gemcitabine for treating malignant pleural mesothelioma. The study involves intrapleural administration of rAd-IFN, aiming to enhance anti-tumor responses. Participants receive rAd-IFN and celecoxib, followed by gemcitabine, with the primary objective of comparing overall survival against a control group receiving only celecoxib and gemcitabine. The trial began in January 2019 and is expected to complete by April 2026.
Tazemetostat, developed by Epizyme Inc., is an oral EZH2 inhibitor under investigation for treating malignant mesothelioma. A Phase 2, open-label study evaluated its efficacy in patients with relapsed or refractory malignant pleural mesothelioma characterized by BAP1 loss-of-function. The trial reported a 54% disease control rate at 12 weeks, with partial responses observed in some patients. Tazemetostat was generally well-tolerated, with manageable side effects such as fatigue and nausea. These findings suggest the potential benefits of tazemetostat for this patient population.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Malignant Mesothelioma Drug Report provides a strategic overview of the latest and future landscape of treatments for malignant mesothelioma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the malignant mesothelioma pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share